Movatterモバイル変換

[0]ホーム
URL:

DE69333127D1 - Variants of the tissue plasminogen activator with improved therapeutic effect - Google Patents

Variants of the tissue plasminogen activator with improved therapeutic effect

Info

Publication number
DE69333127D1
DE69333127D1DE69333127TDE69333127TDE69333127D1DE 69333127 D1DE69333127 D1DE 69333127D1DE 69333127 TDE69333127 TDE 69333127TDE 69333127 TDE69333127 TDE 69333127TDE 69333127 D1DE69333127 D1DE 69333127D1
Authority
DE
Germany
Prior art keywords
variants
plasminogen activator
tissue plasminogen
therapeutic effect
improved therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69333127T
Other languages
German (de)
Other versions
DE69333127T2 (en
Inventor
William F Bennett
Bruce Alan Keyt
Nicholas F Paoni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech IncfiledCriticalGenentech Inc
Application grantedgrantedCritical
Publication of DE69333127D1publicationCriticalpatent/DE69333127D1/en
Publication of DE69333127T2publicationCriticalpatent/DE69333127T2/en
Anticipated expirationlegal-statusCritical
Expired - Lifetimelegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

The invention concerns tissue plasminogen activator (t-PA) variants which are glycosylated at any of positions 103-105, and are devoid of functional carbohydrate structure at position 117 of wild-type human t-PA amino acid sequence. The variants have extended circulatory half-life and substantially retained fibrin binding, or improved in vivo fibrinolytic potency, as compared to wild-type human t-PA. <IMAGE>
DE69333127T1992-06-031993-05-28 Variants of the tissue plasminogen activator with improved therapeutic effectExpired - LifetimeDE69333127T2 (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US89421392A1992-06-031992-06-03
US8942131992-06-03

Publications (2)

Publication NumberPublication Date
DE69333127D1true DE69333127D1 (en)2003-09-04
DE69333127T2 DE69333127T2 (en)2004-05-06

Family

ID=25402765

Family Applications (3)

Application NumberTitlePriority DateFiling Date
DE2001199044ActiveDE10199044I2 (en)1992-06-031993-05-28 Variants of tissue plasminogen activator with improved therapeutic effect
DE69312493TExpired - LifetimeDE69312493T2 (en)1992-06-031993-05-28 VARIANTS OF TISSUE PLASMINOGEN ACTIVATOR WITH IMPROVED THERAPEUTIC EFFECT
DE69333127TExpired - LifetimeDE69333127T2 (en)1992-06-031993-05-28 Variants of the tissue plasminogen activator with improved therapeutic effect

Family Applications Before (2)

Application NumberTitlePriority DateFiling Date
DE2001199044ActiveDE10199044I2 (en)1992-06-031993-05-28 Variants of tissue plasminogen activator with improved therapeutic effect
DE69312493TExpired - LifetimeDE69312493T2 (en)1992-06-031993-05-28 VARIANTS OF TISSUE PLASMINOGEN ACTIVATOR WITH IMPROVED THERAPEUTIC EFFECT

Country Status (20)

CountryLink
US (1)US5612029A (en)
EP (2)EP0786257B1 (en)
JP (1)JP3559559B2 (en)
AT (2)ATE246000T1 (en)
AU (1)AU664469B2 (en)
CA (1)CA2129660C (en)
DE (3)DE10199044I2 (en)
DK (2)DK0643772T3 (en)
EE (1)EE03128B1 (en)
ES (2)ES2203668T3 (en)
FI (1)FI117940B (en)
GE (1)GEP20012448B (en)
GR (1)GR3024806T3 (en)
HK (1)HK1000449A1 (en)
IL (1)IL105883A (en)
LU (1)LU90800I2 (en)
NL (1)NL300050I2 (en)
NZ (1)NZ253556A (en)
PT (1)PT786257E (en)
WO (1)WO1993024635A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US7060484B1 (en)1993-11-122006-06-13Gilead Sciences, Inc.Polypeptides and coagulation therapy
DE69434332T2 (en)*1993-11-122006-02-02Gilead Sciences, Inc., Foster City THROMBIN MUTANTS
US5605793A (en)1994-02-171997-02-25Affymax Technologies N.V.Methods for in vitro recombination
US5510330A (en)†1994-03-251996-04-23Boehringer Mannheim GmbhCombinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
DE4423574A1 (en)*1994-07-051996-01-11Boehringer Mannheim Gmbh Non-glycosylated plasminogen activator derivatives and their use when there is an increased risk of bleeding
US5945432A (en)*1995-12-221999-08-31The University Of Vermont And State Agricultural CollegeThrombolytic agents and thienopyridine derivatives in acute stroke
AU2660397A (en)*1996-04-051997-10-29Board Of Regents, The University Of Texas SystemMethods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US6083715A (en)*1997-06-092000-07-04Board Of Regents, The University Of Texas SystemMethods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
WO1999023115A1 (en)*1997-10-311999-05-14Eli Lilly And CompanyGlycosylated obesity protein analogs
US6242473B1 (en)1999-01-082001-06-05Maxim Pharmaceuticals, Inc.Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
CN1167808C (en)1999-11-042004-09-22杰南技术公司Reversed-phase HPLC assay for plasminogen activators
US20030036181A1 (en)*2000-06-302003-02-20Okkels Jens SigurdPeptide extended glycosylated polypeptides
JP2005508366A (en)*2001-11-062005-03-31マキシム ファーマシューティカルス，インコーポレイテッド Composition for the treatment of infectious diseases
MXPA04004948A (en)*2001-11-262004-08-11Genentech IncCatheter composition and uses thereof.
US7084118B2 (en)*2002-02-222006-08-01Genentech, Inc.Combination treatment with t-PA variant and low molecular weight heparin
US20060105387A1 (en)*2002-08-302006-05-18Prior Christopher PTransferrin fusion proteins libraries
US20070014779A1 (en)*2002-11-142007-01-18Genentech, Inc.Plasminogen activator variant formulations
US7553930B2 (en)2003-01-062009-06-30Xencor, Inc.BAFF variants and methods thereof
US20060104969A1 (en)*2004-08-162006-05-18Massachusetts Institute Of TechnologyCompositions and methods for enhancing structural and functional nervous system reorganization and recovery
RU2007147921A (en)*2005-06-022009-07-20Эйвестаджен Лимитед,In (In) OPTIMIZED METHOD FOR PRODUCING A RECOMBINANT FORM OF PLASMINOGEN TISSUE ACTIVATOR
US7932084B2 (en)*2005-09-082011-04-26University Of Virginia Patent FoundationMethods and compositions for growing adipose stem cells
WO2007120818A2 (en)*2006-04-122007-10-25Massachusetts Institute Of TechnologyCompositions and methods for inhibiting adhesions
JP2009533458A (en)*2006-04-142009-09-17マサチューセッツ インスティテュート オブ テクノロジー Identification and modulation of molecular pathways that mediate plasticity of the nervous system
MX2009001918A (en)2006-08-292009-03-06Genentech IncUse of tenecteplase for treating acute ischemic stroke.
KR20090086066A (en)*2006-10-062009-08-10유니버시티 오브 버지니아 페이턴트 파운데이션 Useful methods and compositions for the treatment of diabetic wounds
JP5871449B2 (en)2006-11-072016-03-01ジェネンテック， インコーポレイテッド Use of tissue plasminogen activator variants
KR100834561B1 (en)2006-12-082008-06-02가톨릭대학교 산학협력단 Non-glycosylated recombinant protein consisting of Kringle domains 1 and 2, preparation method thereof, and composition comprising the same
EP2289542A1 (en)2009-08-312011-03-02PAION Deutschland GmbHTreatment of neurological or neurodegenerative disorders
EP2289541A1 (en)2009-08-312011-03-02PAION Deutschland GmbHTreatment of neurological or neurodegenerative disorders
US20130122076A1 (en)*2011-11-112013-05-16Mathew GelfandTransdermal Patch Having Ultrasound Transducer for Administering Thrombolytic Reagents to Patients Having a Protein Misfolding Disease
IN2015MN00047A (en)2012-07-052015-10-16Hadasit Med Res Service
EP2928480B1 (en)2012-12-052019-09-25National Jewish HealthTreatment for airway cast obstruction
CN103159860B (en)*2013-04-072014-09-24旭华（上海）生物研发中心有限公司 Recombinant tissue-type plasminogen activator and its preparation method and application
WO2015023830A1 (en)2013-08-142015-02-19Stc.UnmTreatment and prevention of stroke and other neurological disorders
US11213574B2 (en)2014-11-032022-01-04Thrombolytic Science, LlcMethods for safe and effective thrombolysis using sequential administration of tissue plasminogen activator and mutant pro-urokinase
BR112019016065A8 (en)2017-02-032022-10-18Acticor Biotech INHIBITION OF PLATELET AGGREGATION USING GPVI ANTI-HUMAN ANTIBODIES
EP3624832B1 (en)2017-05-162025-08-20Institut National de la Santé et de la Recherche MédicaleMethods and pharmaceutical compositions for the treatment of acute ischemic stroke
WO2018232305A1 (en)2017-06-162018-12-20Thrombolytic Science, LlcMethods and compositions for thrombolysis
EP3806833A1 (en)2018-06-152021-04-21INSERM (Institut National de la Santé et de la Recherche Médicale)Use of pi3kc2b inhibitors for the preservation of vascular endothelial cell barrier integrity
WO2021148439A1 (en)2020-01-212021-07-29INSERM (Institut National de la Santé et de la Recherche Médicale)Methods for stimulating cerebrovascular function
WO2021249974A1 (en)2020-06-092021-12-16INSERM (Institut National de la Santé et de la Recherche Médicale)Fucoidan-functionalized polysaccharide particles with t-pa for targeted thrombolytic therapy
US20250154252A1 (en)2022-02-212025-05-15Acticor BiotechTreatment of cardiovascular diseases using anti-human gpvi antibodies
WO2024229429A1 (en)2023-05-042024-11-07Genentech, Inc.Use of tenecteplase for treating late-window stroke patients
WO2025064654A1 (en)*2023-09-192025-03-27The Research Foundation For The State University Of New YorkTruncated tissue plasminogen activator proteins and use thereof
EP4556492A1 (en)2023-11-142025-05-21Acticor BiotechTreatment of cardiovascular diseases using anti-human gpvi antibodies in subpopulations of subjects

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
USRE30985E (en)1978-01-011982-06-29Serum-free cell culture media
ZA811368B (en)1980-03-241982-04-28Genentech IncBacterial polypedtide expression employing tryptophan promoter-operator
NL8003402A (en)1980-06-111982-01-04Leuven Res & Dev Vzw NEW PLASMINOGEN ACTIVATOR AND PHARMACEUTICAL PREPARATION WITH THROMBOLYTIC ACTION.
GR79202B (en)1982-05-051984-10-22Genentech Inc
US4766075A (en)1982-07-141988-08-23Genentech, Inc.Human tissue plasminogen activator
US4943529A (en)1982-05-191990-07-24Gist-Brocades NvKluyveromyces as a host strain
EP0125269A1 (en)*1982-11-111984-11-21Beecham Group PlcPharmaceutically active compounds
EP0112122B1 (en)*1982-12-141991-08-28South African Inventions Development CorporationPlasminogen activator
US4560655A (en)1982-12-161985-12-24Immunex CorporationSerum-free cell culture medium and process for making same
US4657866A (en)1982-12-211987-04-14Sudhir KumarSerum-free, synthetic, completely chemically defined tissue culture media
AU3145184A (en)1983-08-161985-02-21Zymogenetics Inc.High expression of foreign genes in schizosaccharomyces pombe
US4767704A (en)1983-10-071988-08-30Columbia University In The City Of New YorkProtein-free culture medium
US4658830A (en)*1984-08-081987-04-21Survival Technology, Inc.Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
US4753879A (en)*1984-08-271988-06-28Biogen N.V.Modified tissue plasminogen activators
FI89723C (en)*1984-10-011993-11-10Genzyme Corp Method for Preparation of Tissue Plasminogen Activator, Encoding Recombinant DNA Them and a Transformation Cell
DE3537176C2 (en)*1984-10-181994-06-09Zymogenetics Inc Tissue plasminogen activator and process for its manufacture
US4879231A (en)1984-10-301989-11-07Phillips Petroleum CompanyTransformation of yeasts of the genus pichia
EP0201153A3 (en)*1985-02-091987-10-07Beecham Group PlcModified enzyme and process for its preparation
US4683195A (en)1986-01-301987-07-28Cetus CorporationProcess for amplifying, detecting, and/or-cloning nucleic acid sequences
NZ215660A (en)*1985-04-041990-03-27Beecham Group PlcTissue plasminogen activator modified in the growth factor domain
ATE68825T1 (en)*1985-04-221991-11-15Genentech Inc HUMAN TISSUE PLASMINOGEN ACTIVATOR MUTANT, PROCESSES AND INTERMEDIATE PRODUCTS THEREOF, AND COMPOSITIONS USING SUCH MUTANT.
GR861365B (en)*1985-05-281986-09-29Wellcome FoundNovel formulation
US4929444A (en)*1985-05-281990-05-29Burroughs Wellcome Co.Low pH pharmaceutical formulation containing t-PA
GB8516415D0 (en)1985-06-281985-07-31Celltech LtdCulture of animal cells
ZW14486A1 (en)*1985-07-291986-10-22Smithkline Beckman CorpPharmaceutical dosage unit
US4960702A (en)*1985-09-061990-10-02CodonMethods for recovery of tissue plasminogen activator
DE3687255T2 (en)*1985-09-101993-05-06Eisai Co Ltd COMPOSITION CONTAINING A TISSUE PLASMINOGEN ACTIVATOR.
GB8528321D0 (en)*1985-11-181985-12-24Ciba Geigy AgModified fibrinolytic agents
ATE85081T1 (en)*1985-12-201993-02-15Upjohn Co ANALOGS OF TISSUE SPECIFIC PLASMINOGEN ACTIVATOR.
DE3684680D1 (en)1985-12-231992-05-07Chiron Corp PEPTIDE PLASMINOGEN ACTIVATORS.
DK43387A (en)*1986-01-291987-07-30Beecham Group Plc FIBRINOLYTIC ENZYM
WO1987004722A1 (en)*1986-01-311987-08-13Genetics Institute, Inc.Novel thrombolytic proteins
IE81073B1 (en)*1986-03-182000-01-12Genentech IncModified human tissue-type plasminogen activator and its preparation
US4927762A (en)1986-04-011990-05-22Cell Enterprises, Inc.Cell culture medium with antioxidant
PT84588B (en)1986-04-021989-05-09Beecham Group PlcProcess for preparing a fibrinolytic enzyme
AU7090687A (en)1986-04-021987-10-08Beecham Group PlcModified tissue-type plasminogen activators
PT84589B (en)*1986-04-021989-05-09Beecham Group PlcProcess for preparing a fibrinolytic enzyme
DE3643158A1 (en)*1986-04-211987-11-19Boehringer Mannheim Gmbh TISSUE PLASMINOGEN ACTIVATOR (TPA) DERIVATIVE AND ITS PRODUCTION
JPH0761266B2 (en)*1986-07-031995-07-05株式会社ミドリ十字 Mutant human prourokinase
DK345087A (en)*1986-07-111988-01-12Novo Industri As MODIFIED TEXTILE PLASMINOGEN ACTIVATOR
GB8619098D0 (en)*1986-08-051986-09-17Wellcome FoundCombination
EP0266032A1 (en)*1986-08-291988-05-04Beecham Group PlcModified fibrinolytic enzyme
WO1988005081A2 (en)*1986-12-301988-07-14Cetus CorporationNovel plasminogen activator
GB8705377D0 (en)*1987-03-071987-04-08Beecham Group PlcCompounds
FI882407L (en)*1987-05-221988-11-23Zymogenetics Inc FIBRINOLYTIC PROTEINS.
DK302288A (en)*1987-06-041989-02-03Zymogenetics Inc Tissue Plasma Minogen Activator with Modified Circumstances
NO179874C (en)*1987-06-041997-01-02Zymogenetics Inc A method of producing a t-PA analog, DNA sequence encoding the t-PA analog, and an expression vector comprising the DNA sequence and host cell comprising this
SE8702562L (en)*1987-06-181988-12-19Kabigen Ab NEW FIBRINOLYTIC ENZYMES
KR960015610B1 (en)*1987-06-221996-11-18제네틱스 인스티튜트, 인코포레이티드 New method for preparing thrombolytic protein
US4935237A (en)1988-03-211990-06-19Genentech, Inc.Processes for the preparation of t-PA mutants
EP0365597B2 (en)*1987-06-302005-02-09Genentech, Inc.Improved processes for the treatment of vascular disease
JPH03500002A (en)*1987-07-061991-01-10ジェネティックス・インスチチュート・インコーポレーテッド Novel thrombolytic protein
AU1893988A (en)*1987-07-131989-01-19Collaborative Research Inc.Nonglycosylated plasminogen activator and method of preparation
CA1308377C (en)1987-08-211992-10-06Henry Berger, Jr.Complex of polyethyleneglycol and tissue plasminogen activator
IL88247A0 (en)1987-11-061989-06-30Genentech IncNovel human tissue-type plasminogen activator variant
US5225540A (en)1988-04-261993-07-06Du Pont Merck Pharmaceutical CompanyMonoclonal antibodies to tissue plasminogen activator (t-pa) which prolong its functional half-life
US5270198A (en)*1988-05-201993-12-14Genentech, Inc.DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
IL90146A (en)1988-05-201994-10-07Genentech IncTissue plasminogen activator glycosylation variants
US5342616A (en)*1988-06-201994-08-30The Wellcome Foundation LimitedMethod of administering tissue plasminogen activator
GB8815135D0 (en)*1988-06-241988-08-03British Bio TechnologyProteins & nucleic acids
DK395288D0 (en)*1988-07-151988-07-15Novo Industri As PROTEINS
US5258180A (en)*1988-09-021993-11-02Genetech, Inc.Tissue plasminogen activator having fibrin specific properties and deletion of amino acids 466-970, compositions and methods of treatment
US5108901A (en)*1988-09-021992-04-28Genentech, Inc.Tissue plasminogen activator having zymogenic or fibrin specific properties
US5262170A (en)*1988-09-021993-11-16Genentech, Inc.Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
EP0435911B1 (en)1988-09-231996-03-13Cetus Oncology CorporationCell culture medium for enhanced cell growth, culture longevity and product expression
US5218092A (en)*1988-09-291993-06-08Kyowa Hakko Kogyo Co., Ltd.Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5041376A (en)*1988-12-091991-08-20The Board Of Regents Of The University Of Texas SystemMethod for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US4980165A (en)*1989-01-271990-12-25Genetics Institute, Inc.Pharmaceutical formulations of plasminogen activator proteins
ATE199090T1 (en)*1989-03-062001-02-15Univ Texas T-PA MUTANTS RESISTANT TO OWN INHIBITORS
US5304482A (en)*1989-03-061994-04-19The Board Of Regents Of The University Of Texas SystemSerine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
ES2038579T3 (en)1989-04-281997-02-16Rhein Biotech Proz & Prod Gmbh YEAST CELLS OF THE GENUS SCHWANNIOMYCES.
FR2649120B1 (en)1989-06-301994-01-28Cayla NOVEL STRAIN AND ITS MUTANTS OF FILAMENTOUS MUSHROOMS, PROCESS FOR PRODUCING RECOMBINANT PROTEINS USING SAID STRAIN, AND STRAINS AND PROTEINS OBTAINED BY SAID METHOD
US5087572A (en)1989-12-011992-02-11Genentech, Inc.Dna encoding human plasminogen modified at the cleavage site
US5366730A (en)*1989-12-201994-11-22Boehringer Mannheim GmbhStabilized compositions having human tissue type plasminogen activator enzymatic activity
DE3942142A1 (en)*1989-12-201991-06-27Boehringer Mannheim Gmbh STABILIZATION OF GLYCOSYLATED T-PA
JP3126381B2 (en)1990-07-312001-01-22ジェネンテク，インコーポレイテッド Tissue plasminogen activator mutant with reduced clearance
US5246850A (en)*1990-07-311993-09-21Genentech, Inc.DNA molecules encoding human tissue plasminogen activator variants with decreased clearance, vectors, and host cells
US5242688A (en)*1990-12-241993-09-07Eli Lilly And CompanyMethod of treating thromboembolic disorders by administration of diglycosylated t-pa variants

Also Published As

Publication numberPublication date
NL300050I1 (en)2001-10-01
CA2129660C (en)2005-06-28
HK1001190A1 (en)1998-05-29
DK0643772T3 (en)1998-02-02
EP0643772A1 (en)1995-03-22
ES2107041T3 (en)1997-11-16
ATE246000T1 (en)2003-08-15
HK1000449A1 (en)2004-03-05
CA2129660A1 (en)1993-12-09
NL300050I2 (en)2001-11-01
EE03128B1 (en)1998-10-15
FI943632L (en)1994-10-04
IL105883A (en)2003-04-10
GEP20012448B (en)2001-05-25
NZ253556A (en)1995-11-27
DE69333127T2 (en)2004-05-06
LU90800I2 (en)2001-10-08
ES2203668T3 (en)2004-04-16
DK0786257T3 (en)2003-10-06
DE10199044I1 (en)2002-02-21
EP0786257A1 (en)1997-07-30
AU664469B2 (en)1995-11-16
PT786257E (en)2003-12-31
EP0643772B1 (en)1997-07-23
FI117940B (en)2007-04-30
EP0786257B1 (en)2003-07-30
FI943632A0 (en)1994-08-04
ATE155816T1 (en)1997-08-15
JPH07507448A (en)1995-08-24
AU4397393A (en)1993-12-30
US5612029A (en)1997-03-18
DE69312493D1 (en)1997-09-04
IL105883A0 (en)1993-10-20
DE69312493T2 (en)1998-01-15
DE10199044I2 (en)2006-02-09
WO1993024635A1 (en)1993-12-09
GR3024806T3 (en)1998-01-30
JP3559559B2 (en)2004-09-02

Similar Documents

PublicationPublication DateTitle
DE69333127D1 (en) Variants of the tissue plasminogen activator with improved therapeutic effect
BE2013C033I2 (en)
IL80659A (en)Modified tissue plasminogen activators,their preparation and pharmaceutical compositions containing them
ES2042693T3 (en) PROTEIN FORMULATIONS OF PLASMA AND RECOMBINANTS IN LOW IONIC POWER MEDIA.
DK0383417T3 (en) Flag salivary plasminogen activator v-PAalfa1
DE69113049D1 (en) VARIANTS OF THE TISSUE PLASMINOGEN ACTIVATOR WITH REDUCED DISASSEMBLY.
FI880891A7 (en) Composition of recombinant human tissue plasminogen activator.
EP0386240A4 (en)Novel polypeptide compounds
NO880831D0 (en) RECOMBINANT HUMAN Tissue PLASMINOGEN ACTIVATOR MIXTURE.
DE69105213D1 (en) SUBSTITUTION VARIANT OF THE TISSUE PLASMINOGEN ACTIVATOR.

Legal Events

DateCodeTitleDescription
8364No opposition during term of opposition
[8]ページ先頭
©2009-2025 Movatter.jp